Reig Jofre It obtained a consolidated net profit of 3.7 million euros in the first quarter, which represents a 12% increase compared to the same period of 2024. The pharmaceutical company attributes the rebound of profits to operational improvements and the positive impact of the participated projects.
The company, which is quoted in the continuous market, registered a Gross exploitation result (EBITDA) of 9.9 million euros Between January and March, 4% lower than the same period last year, with a margin of 11.2% on sales. The income stood at 88 million euros, 2% more than a year earlier, “in a transition period and operational improvements focused on increasing profitability and consolidating its global expansion,” the company explained this Friday to the National Securities Market Commission (CNMV).
The pharmacist has indicated that the growth of its income was led by the Consumer Healthcare division, which advanced 9% between until March, and was also driven by its international expansion. So, The markets from outside Spain already represent 60% of income of the company, with a growth of 11% compared to the same period of the previous year.
This advance, the company has specified, reflects its Strategy to reduce its national market dependence. In fact, Spain contributed 35 million euros of sales, with a 10% decrease and a lower relative weight. By regions, the pharmacist has highlighted the growth of the income of 12% in the rest of Europe, with 43 million euros, especially driven by the good behavior of countries such as Poland and Sweden. In the rest of the world, sales increased by 10%, adding 10 million euros, with a relevant contribution of the Asian market.
During the first quarter of the year, the company allocated 2.5 million euros to industrial investmentmainly at the Toledo plant, with the aim of increasing productivity and reducing unit costs. The gross financial debt of Reig Jofre stood at 65 million euros at the end of March, 3% lower than that existing at the end of 2024, while the net financial debt amounted to 58.2 million euros, in line with the closure of 2024. At the end of April this year, the actions of the pharmacist accumulate a revaluation of 17% so far this year, with a stock capitalization of 235 million. of euros.
Reig Jofre has also reported that the Board of Directors approved yesterday the conditions of execution of the increase in capital released to formalize its Flexible dividend of 0.05 euros per share char for voluntary reservesfigure equivalent to approximately 39% of the net result. The maximum number of new shares to be issued has been set at 1,348,262 titles, for a total nominal amount of 674,131 euros. However, the definitive figures will depend on the number of preferential subscription rights that are finally subject to conversion into actions.
The payment of cash to those shareholders who had chosen to receive the entire or part of the cash dividend under the purchase commitment is initially expected for June 2. The date provided for the start of the ordinary contracting of the new actions created by virtue of the capital increase is estimated to be on June 26. Reig Jofre Board of Directors has appointed Sabadell Bank as the Entity of the Issuance.
#Reig #Jofre #earns #million #euros #quarter
